Pituitary adenomas (PAs), the most common intracranial neuroendocrine tumors, are generally benign. Prolactinomas, which secrete prolactin, represent approximately 60% of all PAs and are characterized by hyperprolactinemia and the potential for mass effects. Significant differences exist between male and female prolactinoma patients in terms of epidemiology and clinical characteristics. Prolactinomas in male patients are often large and aggressive, posing unique challenges for treatment and management. While dopamine agonists (DAs) are the traditional first-line therapy for prolactinomas, men are more prone to DA resistance than women. Alternative therapeutic options for refractory prolactinomas in men include temozolomide (TMZ), immune checkpoint inhibitors (anti-PD1/PD-L1 and anti-CTLA4), somatostatin receptor analogs, mTOR inhibitors, tyrosine kinase inhibitors, bevacizumab, and aromatase inhibitors. These treatments may offer greater benefit to men with refractory prolactinomas compared to women. Despite progress, significant opportunities and challenges remain for treating male prolactinomas patients. These include early diagnosis, predicting drug sensitivity, understanding gender-driven molecular mechanisms, and developing novel therapeutic strategies. Large-scale clinical trials are essential to further evaluate the efficacy and safety of these therapies in men with prolactinomas. This review summarizes recent advancements in understanding medical treatments and management approaches for male prolactinoma patients.
S. Karger AG, Basel.